Summary of First Financial Bancorp (FFBC) Conference Call on Acquisition of Westfield Bancorp Company and Industry - **Company**: First Financial Bancorp (FFBC) - **Acquisition Target**: Westfield Bancorp - **Industry**: Banking and Financial Services Core Points and Arguments 1. **Acquisition Announcement**: FFBC announced the acquisition of Westfield Bancorp from Ohio Farmers Insurance Company, enhancing its presence in the Cleveland, Ohio market [2][3] 2. **Financial Impact**: The acquisition will more than triple FFBC's loan commitments in Northeast Ohio to approximately $1.5 billion and add $1.5 billion in local deposits [3][4] 3. **Branch Network and Talent**: The deal provides FFBC with a highly efficient branch network and talent across multiple business lines, positioning it as a premium alternative to larger banks [3][4] 4. **Earnings Accretion**: The acquisition is financially attractive with strong earnings accretion and a tangible book value earn back within acceptable parameters [4][8] 5. **Asset Quality**: Westfield has a strong record regarding asset quality, with net charge-offs averaging four basis points over the last five years, aligning with FFBC's lending and credit administration approach [5][6] 6. **Market Position**: Post-acquisition, FFBC will become the fourth largest Ohio-based banking company and the only community bank among the top eight banks in the state [6][8] 7. **Transaction Structure**: The transaction is structured as approximately 80% cash and 20% stock, with shareholder approval from Ohio Farmers already received [7][8] 8. **Future Growth Opportunities**: FFBC anticipates significant growth opportunities in consumer lending, wealth management, and specialty banking post-acquisition [10][49] Additional Important Content 1. **Cultural Compatibility**: Both companies share a strong commitment to associates, clients, and communities, which is expected to facilitate the integration process [5][6] 2. **Cost Savings and Renovations**: Initial branch renovations are estimated at $800,000, with plans for branding refreshes post-merger [17][18] 3. **NIM Strategy**: FFBC aims to rebuild the net interest margin (NIM) to around 4% by remixing acquired loans and enhancing commercial product offerings [19][20] 4. **Credit Quality**: The acquisition is expected to slightly improve charge-off rates due to Westfield's strong credit history [41][42] 5. **Future Acquisition Appetite**: FFBC remains open to future acquisitions, depending on size and timing, while maintaining a target tangible common equity (TCE) ratio of 7.5% [30][54] 6. **CECL Adoption**: The impact of the new CECL accounting standard is currently uncertain, but it is not expected to significantly affect the acquisition due to Westfield's clean credit profile [61][62] This summary encapsulates the key points discussed during the conference call regarding the acquisition of Westfield Bancorp by First Financial Bancorp, highlighting the strategic, financial, and operational implications of the deal.

Summary of Waste Management (WM) 2025 Investor Day Company Overview - **Company**: Waste Management (WM) - **Event**: 2025 Investor Day - **Date**: June 24, 2025 - **Key Speaker**: Jim Fish, CEO Core Industry Insights - **Industry**: Waste Management and Environmental Services - **Market Position**: WM is positioned as a leader in the waste management industry with a unique asset network and materials management expertise [19][24][34] Key Financial Metrics - **2024 Revenue**: $22.1 billion [19] - **2024 EBITDA**: $6.6 billion [19] - **Historical Performance**: - 3% revenue growth during the pandemic - 7% adjusted operating EBITDA growth during the pandemic - 14% free cash flow growth during the pandemic - 6% top-line growth from 2022 to 2024 - 9% EBITDA growth from 2022 to 2024 - 13% free cash flow growth from 2022 to 2024 [20][21] Strategic Focus Areas - **People First Leadership**: Emphasis on valuing employees and fostering a dynamic leadership team [17][18] - **Long-term Growth Strategy**: Focus on sustainable value creation through disciplined capital allocation and operational excellence [18][64] - **Customer-Centric Approach**: Commitment to customer service and satisfaction as a core business principle [32][34] Operational Excellence - **Cost Management**: Operating expenses as a percentage of revenue reduced from 65% to 60% [31][69] - **Technology Integration**: Implementation of advanced technologies to improve operational efficiency and safety [74][80] - **Fleet Optimization**: Use of telematics and real-time data to enhance fleet management and reduce downtime [84][86] Growth Platforms - **Sustainability Initiatives**: Planned investment of $3 billion in recycling and renewable natural gas (RNG) plants, with expected incremental free cash flow of $600 million to $630 million from these investments [45][46] - **Healthcare Solutions**: Expansion into healthcare waste management, leveraging demographic trends and increasing healthcare spending [47][54] Market Trends and Challenges - **Labor Market**: Addressing labor shortages through technology and automation, including the transition to automated side loaders and autonomous vehicles [58][62] - **Landfill Capacity**: Anticipating a reduction in landfill capacity over the next 20 years, while maintaining a competitive disposal network [36][38] Competitive Landscape - **Consolidation Opportunities**: Potential for tuck-in acquisitions within the industry, with a focus on expanding operations in underserved areas [42][44] - **Regulatory Expertise**: Leveraging regulatory knowledge to navigate industry challenges and enhance service offerings [34] Conclusion - **Investment Thesis**: WM is positioned for sustained growth through a combination of strong leadership, operational excellence, and strategic investments in sustainability and healthcare solutions [64]

Summary of Nektar Therapeutics Conference Call Company and Industry - **Company**: Nektar Therapeutics - **Industry**: Biotechnology, specifically focusing on treatments for autoimmune and inflammatory conditions, with a current emphasis on dermatological diseases such as atopic dermatitis and alopecia areata Core Points and Arguments 1. **Therapeutic Strategy**: Nektar's strategy focuses on advancing innovative therapies for serious autoimmune and inflammatory conditions, particularly through immune system rebalancing to achieve immune homeostasis for patients [6][46] 2. **Rezpeg Overview**: Rezpeg is a first-in-class Treg stimulator based on IL-2, validated as a best-in-class approach for treating atopic dermatitis, differentiating itself from other IL-2 agonists [6][7] 3. **Clinical Trial Results**: The Phase IIb trial for Rezpeg in atopic dermatitis showed statistically significant results across primary and secondary endpoints, with a p-value of less than 0.001 for the primary endpoint [7][16] 4. **Efficacy Metrics**: - The trial met its primary endpoint of mean improvement in EASI score at week sixteen for all three arms of Rezpeg versus placebo - Key secondary endpoints such as EZ75, EZ50, and BSA also achieved statistical significance [7][17] - The highest dose of 24 micrograms per kilogram every two weeks achieved significance on the EZ90 endpoint [7][17] 5. **Rapid Onset of Response**: A rapid onset of response was observed, particularly for EZ75 and itch, differentiating Rezpeg from other immune modulation approaches [8][19] 6. **Safety Profile**: The safety profile was consistent with previous results, with less than 1% of patients discontinuing due to injection site reactions (ISRs) and no increased incidence of conjunctivitis or infections compared to placebo [8][26] 7. **Translational Data**: Rezpeg reduced key Th2-related inflammatory markers associated with atopic dermatitis, indicating a meaningful immunological impact [21][22] 8. **Future Studies**: Nektar is eager to evaluate Rezpeg in alopecia areata, with results expected in Q4 2023, and plans to present 52-week maintenance data in early 2026 [9][49] Additional Important Content 1. **Patient Demographics**: The study enrolled 393 biologic-naive patients with moderate to severe atopic dermatitis, predominantly from Europe, North America, and Australia [10][14] 2. **Placebo Response Rate**: The low placebo response rate of 31% was noted as a significant achievement, indicating effective management of placebo effects [17][66] 3. **Dosing Strategy**: The company is considering a single dose level for Phase III based on the successful dose range observed in Phase IIb [62][63] 4. **Potential for Other Indications**: Nektar sees potential for Rezpeg in other dermatological conditions such as lupus and vitiligo, as well as in type 1 diabetes [51][52] 5. **ISR Mitigation Strategies**: Nektar is planning to implement strategies to mitigate ISRs, including the use of an auto-injector for self-administration [28][81] 6. **Expert Opinions**: Key opinion leaders expressed confidence in the study design and results, highlighting the potential for sustained and deepening responses in future studies [44][70] This summary encapsulates the key points discussed during the conference call, focusing on the efficacy, safety, and future potential of Rezpeg in treating atopic dermatitis and other conditions.

Summary of Conference Call Industry Overview - The discussion primarily revolves around the oil and gas industry, particularly focusing on the impact of the shale revolution on U.S. oil production and energy independence [2][3][4]. Key Company Insights Company Position and Strategy - The company, Kotera, emphasizes its strong position in the market, highlighting its stability in cash flow and low cost of supply, which allows for flexible capital allocation [5][6]. - Kotera has a balanced asset portfolio that enables it to maintain capital efficiency despite price volatility in the oil and gas markets [5][6]. Capital Allocation - The company has adjusted its capital allocation strategy, moving some capital from oil to gas due to market uncertainties, particularly in the Middle East [6][10]. - Kotera can achieve returns at oil prices as low as $50 per barrel, indicating a robust operational efficiency [6][10]. Natural Gas Production - Kotera produces approximately 3 billion cubic feet (BCF) of natural gas per day, with a balanced revenue stream from both oil and gas [11][12]. - The company is actively drilling in the Marcellus and Anadarko regions, with plans to drill 11 wells this year and 17 in the next couple of years [12][13]. Inventory Depth and Growth - Kotera asserts that it has a deep inventory across its three core business units, with a focus on maintaining high-quality inventory for future growth [15][17]. - The company is confident in its ability to grow volumes while investing only 50% of its cash flow, which is a significant improvement from a decade ago when it was outspending its cash flow [16][21]. Mechanical Issues and Response - Kotera faced a mechanical issue with 11 wells in the Harkie shale, which temporarily affected its market cap by approximately $2 billion [22][24]. - The company has identified a solution to the mechanical issue and is optimistic about bringing the affected wells back online [26][32]. Future Outlook - The company maintains its production guidance despite the mechanical issues, indicating a strong operational outlook [38]. - Kotera is redirecting some capital to the more productive Wolfcamp program due to the Harkie issue, which is expected to yield higher returns [39][40]. Regulatory and Market Considerations - The potential reactivation of the Constitution pipeline is a significant factor for Kotera's capital planning, as it could enhance gas transportation and market access [51][52]. - The company is optimistic about the regulatory environment for the Constitution pipeline, which could lead to increased natural gas supply to New England [56][57]. Cash Return Strategy - Kotera plans to maintain its ordinary dividend as a priority, while also focusing on debt reduction following recent acquisitions [60][61]. - The company took on additional debt for acquisitions but aims to pay it off within the year [61][62]. Conclusion - Kotera is positioned well within the oil and gas industry, with a focus on operational efficiency, strategic capital allocation, and addressing mechanical challenges. The company remains optimistic about future growth and market opportunities, particularly in natural gas and pipeline infrastructure.

Summary of Nuvalent Conference Call Company Overview - **Company**: Nuvalent - **Focus**: Development of targeted therapies for cancer, specifically for ROS1 positive non-small cell lung cancer (NSCLC) with their product candidate, Zydastantinib [2][5][6] Industry Context - **Industry**: Oncology, specifically targeting ROS1 positive non-small cell lung cancer - **Current Landscape**: Four FDA approved therapies exist for ROS1 positive NSCLC, each with limitations such as inadequate CNS penetrance and resistance mutations [10][11] Key Points and Arguments Product Development and Clinical Trials - **Zydastantinib**: First and only ROS1 selective compound designed to address key medical needs, including CNS penetrance and resistance mutations [12][8] - **ARRIS-one Trial**: Ongoing clinical trial evaluating Zydastantinib, with a focus on heavily pretreated patients [12][13] - **Enrollment**: As of September 2023, enrollment in the Phase II portion began, targeting both TKI pretreated and naive patients [13][14] Clinical Data Highlights - **Efficacy**: - Overall response rate (ORR) in TKI pretreated patients was 44%, with a duration of response (DOR) rate of 62% at 18 months [17][18] - In patients who received prior crizotinib only, ORR was 68% with no progression events among responders [21][43] - In TKI naive patients, ORR was 89% with a DOR rate of 96% at 12 months [27][28] - **CNS Activity**: - Intracranial ORR was 48% in patients with measurable CNS lesions, with a complete response (CR) rate of 20% [23][24] - In patients who received crizotinib only, intracranial ORR was 85% [24][49] Safety Profile - **Adverse Events**: Zydastantinib was generally well tolerated, with low rates of dose modifications (10%) and discontinuations (2%) due to adverse events [25][26] - **Common Adverse Events**: Peripheral edema (36%), constipation (17%), and fatigue (16%) were the most frequently reported [25] Regulatory and Commercial Strategy - **NDA Submission**: Planned rolling submission for Zydastantinib in July 2025, targeting TKI pretreated patients [29] - **FDA Engagement**: Participation in the Real Time Oncology Review (RTOR) pilot program to expedite the review process [29] - **Commercial Readiness**: Preparations for a potential launch in 2026, including building commercial teams and identifying key prescribers [30] Future Directions - **Broader Portfolio**: Nuvalent is advancing additional programs for ALK positive NSCLC and HER2 altered NSCLC, with pivotal data expected later in 2025 [31][32][33] - **Clinical Development Speed**: Rapid enrollment and execution of the ARRIS-one study, reflecting strong interest and support from the medical community [78] Additional Important Insights - **Market Opportunity**: The unique design of Zydastantinib aims to address unmet needs in the ROS1 NSCLC space, potentially leading to a compelling commercial opportunity [30][31] - **Comparative Advantage**: Zydastantinib's selective design aims to minimize off-target effects and improve patient tolerability compared to existing therapies [60][61] This summary encapsulates the critical aspects of Nuvalent's conference call, highlighting the company's innovative approach to treating ROS1 positive NSCLC and the promising data emerging from their clinical trials.

Veradigm (MDRX) Investor Update Conference Call Summary Company Overview - **Company**: Veradigm (MDRX) - **Date of Call**: June 24, 2025 - **Key Speakers**: Tom Langan (Interim CEO), Lee Westerfield (Interim CFO) Key Industry Insights - **Industry**: Healthcare Technology - **Market Demand**: Positive signs of growth in new business, particularly in payer and provider markets, indicating strong market demand for Veradigm's solutions and services [4][5][11] Core Financial Highlights - **Annual Contract Value**: Signed deals valued at over $30 million in annual contract value with new customers in Q1 2025 [4] - **Revenue Performance**: Estimated revenue for Q1 2025 is between $145 million to $147 million, reflecting a 1% increase year-over-year [22] - **Recurring Revenue**: Approximately 78% of total revenue is recurring, consistent with previous year [22] - **Provider Segment Revenue**: Estimated revenue from the provider segment is between $113 million to $115 million, essentially flat compared to the prior year [22] - **Payer and Life Science Revenue**: Estimated revenue in this segment is between $31 million to $32 million, an 8% increase year-over-year [22] Strategic Initiatives - **Product Development**: Continued strengthening of products and solutions, particularly in specialty practices like urology and orthopedics [6][9] - **AI Integration**: Development of AI capabilities aimed at enhancing provider workflow efficiencies and financial enhancements [13][14] - **Operational Improvements**: Implementation of a new ERP system scheduled to go live in 2026, aimed at improving operational efficiency [14][60] Recognition and Awards - **Awards**: Veradigm payer insights received the 2025 CLAS points of light award, and Black Book rated Veradigm payer analytics as the number one provider for health plans [6] Customer Engagement - **Customer Summit**: Increased attendance by over 50% at the Veradigm Customer Summit, indicating strong customer engagement and interest in the company's vision and solutions [10] Challenges and Risks - **Client Attrition**: Client attrition was in line with assumptions, particularly in the larger physician segment, which continues to face challenges [4][54] - **Market Headwinds**: Some headwinds in the life sciences market due to policy changes and R&D investment shifts, but overall positive momentum observed [48][74] Financial Position and Outlook - **Debt Financing**: Entered into a credit agreement providing up to $100 million, with an initial draw of $75 million [28][30] - **Cash Position**: Cash on hand was $272 million as of March 31, 2025, down $23 million from year-end 2024 [24] - **Profitability Outlook**: No specific earnings guidance for 2025 provided, but ongoing cost initiatives are expected to improve profitability in future years [42][59] Conclusion - **Future Plans**: Veradigm aims to regain current status with SEC financial filings by 2026 and plans to continue providing periodic business updates until compliance is achieved [32][36] - **Leadership Transition**: Tom Langan announced his departure from the leadership team, marking the end of his tenure during this call [37][84]

Summary of Revolution Medicines Conference Call Company Overview - **Company**: Revolution Medicines - **Industry**: Biotechnology, specifically focused on targeted therapies for RAS addicted cancers Key Points and Arguments 1. **Partnership with Royalty Pharma**: Revolution Medicines announced a significant partnership with Royalty Pharma, which will provide up to $2 billion in committed capital to support the development of their late-stage pipeline of RAS inhibitors while allowing the company to retain full control of its assets [4][5][6] 2. **Financial Position**: As of March 30, 2025, Revolution Medicines reported $2.1 billion in cash and investments. The partnership with Royalty Pharma adds an additional $2 billion in capital, structured to avoid equity dilution for shareholders [5][6][30] 3. **Funding Structure**: The funding arrangement includes approximately two-thirds in the form of a synthetic royalty and the remainder as corporate debt. The synthetic royalty will provide $1.25 billion in exchange for tiered royalties on future sales of diraxonrasib, with specific milestones triggering access to funds [24][25][29] 4. **Clinical Development Plans**: The company is committed to advancing its pipeline, which includes diraxonrasib, a multi-selective RAS inhibitor, and other candidates targeting various RAS mutations. The focus remains on executing robust global Phase III clinical trials [10][18][19] 5. **Market Focus**: The U.S. market is a strategic priority for Revolution Medicines, with plans to establish a standalone U.S.-based commercial capability. The company also aims to expand into select international markets, including Europe and Japan, using a phased approach [20][21][22] 6. **Regulatory Designation**: Diraxonrasib has received breakthrough therapy designation from the FDA for previously treated metastatic pancreatic cancer with KRAS G12 mutations, indicating strong potential for market impact [33] 7. **Strategic Independence**: Revolution Medicines aims to maintain strategic and execution control over its global commercialization efforts, which is expected to enhance decision-making speed and align strategic priorities without the complications of partnerships [45][46] 8. **Clinical Pipeline**: The company is focused on developing a portfolio of RAS inhibitors, including diraxonrasib, elyronrasib, and zoldonrasib, targeting various cancer types such as pancreatic cancer, non-small cell lung cancer, and colorectal cancer [18][19][73] Additional Important Content 1. **Market Opportunity**: The company recognizes the significant unmet medical need in treating RAS addicted cancers, particularly pancreatic cancer, which has a high prevalence of RAS mutations [19] 2. **Financial Guidance**: Revolution Medicines has withdrawn its previous guidance on expected GAAP net loss for 2025 as it evaluates the accounting treatment of the new funding arrangement [31][94] 3. **Talent Acquisition**: The company is actively growing its organization to support its ambitious clinical and commercialization plans, attracting experienced professionals in the biotechnology field [10][96] 4. **Long-term Vision**: Revolution Medicines is committed to creating an industry-leading targeted medicines franchise for patients with RAS addicted cancers, emphasizing the importance of innovative drug mechanisms and clinical data [33][34] This summary encapsulates the critical insights and strategic direction of Revolution Medicines as discussed in the conference call, highlighting their financial strategies, clinical development plans, and market focus.

Summary of MP Materials Conference Call Company Overview - **Company**: MP Materials - **Industry**: Rare Earth Elements and Permanent Magnets Key Points and Arguments Market Dynamics - The market has rapidly evolved from a lack of knowledge about rare earth elements to a heightened awareness due to geopolitical tensions, particularly between the US and China, and export controls imposed by China on critical products [5][12][16] - Permanent magnets are identified as critical enablers of the modern economy, essential for various applications including electric vehicles, drones, and industrial machinery [5][6] Product Segmentation - The discussion highlights the importance of both light and heavy rare earth elements, with a focus on neodymium and praseodymium (NDPR) as the primary components in permanent magnets [6][7] - Heavy rare earth elements like dysprosium and terbium are also produced, but their growth is expected to be slower compared to light rare earths [10][11] Growth Projections - NDPR and magnets are projected to grow at a double-digit compound annual growth rate (CAGR), while heavy rare earths are expected to grow at a slower pace [10][11] - The demand for permanent magnets is driven by their applications across various sectors, including automotive and defense [10][11] Impact of Export Controls - China's recent export controls have prompted a reevaluation of supply chain dependencies, revealing vulnerabilities in the reliance on Chinese-produced magnets [12][14][16] - The controls have led to a wake-up call for industries that previously took the availability of magnets for granted, highlighting the need for domestic production capabilities [14][16] Competitive Positioning - MP Materials positions itself as a national champion in the rare earth space, emphasizing its vertical integration strategy to enhance competitiveness against Chinese producers [19][20] - The company claims to be the lowest cost producer of mixed earth concentrate globally, with plans to expand refining capabilities [20][21] Investment and Production Capacity - Since going public in February 2020, MP Materials has invested nearly $1 billion in its supply chain across upstream, midstream, and downstream operations [28] - The company aims to produce approximately 6,000 tons of NDPR oxide, which could translate to about 12,000 tons of finished magnets [29][30] Government Initiatives - The company supports government initiatives aimed at fostering domestic production of critical materials, including the Section 232 investigation into the national security implications of rare earth elements [32][35] - There is a recognition of the need for a coordinated government approach to build a robust supply chain in the Western world [36][37] Strategic Partnerships - MP Materials is exploring partnerships to build a fully integrated supply chain, which includes refining capabilities and collaboration with other industry players [24][25][26] Additional Important Insights - The company emphasizes the importance of recycling and closed-loop processes to enhance material efficiency and reduce waste in magnet production [22] - The discussion reflects a broader concern about the geopolitical implications of reliance on a single country for critical materials, advocating for a diversified supply chain [16][19] This summary encapsulates the critical insights from the MP Materials conference call, highlighting the company's strategic positioning, market dynamics, and future growth prospects in the rare earth industry.

Summary of Ivanhoe Electric's Santa Cruz Copper Project Update Company Overview - **Company**: Ivanhoe Electric (IE) - **Project**: Santa Cruz Copper Project - **Location**: Arizona, USA - **Date of Call**: June 23, 2025 Industry Context - The copper mining industry is facing challenges related to supply chain security and national resource independence in the United States - The project aims to address the shortage of modern copper smelters in the U.S. and produce refined copper on-site with minimal environmental impact [4][6][7] Key Points and Arguments 1. **Project Timeline and Development**: - The Santa Cruz project has been in development for approximately 8-9 years and is expected to take about 12-15 years to reach full production [5][20] - The project is designed to produce copper cathode on-site using heap leach technology, which minimizes environmental impacts compared to traditional smelting [7][30] 2. **Economic Viability**: - At a copper price of $4.83 per pound, the project has an after-tax net present value (NPV) of $1.9 billion and an internal rate of return (IRR) of 24% [20] - The project is projected to generate $5 billion in life-of-mine after-tax free cash flow with a payback period of approximately 4.5 years at a $4.25 copper price [21] 3. **Production Capacity**: - The project aims for an average mining rate of 20,000 tons per day and expects to achieve 92% copper recoveries [20] - Average annual copper cathode production during the first 15 years is estimated at 72,000 tons [21] 4. **Resource Estimates**: - The project has defined 136 million tons of probable reserves with an average grade of 1.08% total copper [26] - Significant additional mineral resources exist, indicating potential for future expansion [38] 5. **Infrastructure and Location**: - The project benefits from excellent access to existing infrastructure, including proximity to major highways, rail, and power lines [24] - The location in Arizona provides access to a skilled workforce and a historical context of mining [25] 6. **Environmental Considerations**: - The project is designed to have a small surface footprint and includes plans for an integrated solar and battery storage facility to supply 70% of the mine's electricity demand [25] 7. **Permitting and Regulatory Support**: - The company is actively working on obtaining necessary permits, with strong relationships established with local and state authorities [36] - A letter of support has been received from the U.S. Export-Import Bank, indicating governmental backing for the project [11][43] 8. **Financing Strategy**: - The company is in discussions with various financing institutions and has received a letter of interest for up to $825 million in project debt [43] - The financing strategy includes a combination of structured debt and potential strategic partnerships [44] Additional Important Information - The project is positioned as a critical contributor to U.S. copper supply, addressing both domestic demand and national security concerns [9][10] - The management team has extensive experience in mining finance and operations, enhancing the project's credibility [45] - The company is also pursuing other critical metals exploration projects, indicating a diversified approach to resource development [48] This summary encapsulates the key aspects of Ivanhoe Electric's Santa Cruz Copper Project as discussed in the conference call, highlighting its economic potential, strategic importance, and operational plans.

Cidara Therapeutics (CDTX) Update / Briefing June 23, 2025 08:30 AM ET Speaker0 Greetings. Welcome to Sadara Therapeutics announces positive top line results from its phase two b NAVIGATE trial evaluating CD388, a nonvaccine preventative of seasonal influenza. At this time, all participants will be in listen only mode. A question and answer session will follow today's formal presentation. Reminder, this conference is being recorded. At this time, I'll hand the conference over to Brian Ritchie with Investor ...